At this time for metastatic melanoma patients, there are currently no biomarkers derived from the mechanism of anti‐PD‐1 immunotherapy reliably able to predict clinical benefit, including TMB, tumor‐specific neoantigens, PD‐L1 expression and infiltrating immune cells.16, 17. This evidence concerns the gene CD274 and neoplasm.